Andreas Schmocker, CEO of Odne, proudly announces the appointment of Steve Fanning as an independent board member.
“Steve is joining us with vast leadership experience in dental and endodontics, bringing innovation to the market,” said Schmocker. “We are currently in the process of launching the Odne system in the United States, and Steve’s background in building businesses in endodontics will be a tremendous asset as we look to expand Odne’s presence.”
Stephen C. Fanning, member of the board, Odne
“I am honored and energized to be collaborating with the talented team at Odne to bring innovation to dentistry/endodontics,” said Fanning. “It is an exciting time to become a part of the Odne team as we look to transform endodontics. The Odne system has the potential to empower clinicians to perform endodontic procedures with more confidence and enable them to provide patients with better outcomes. I couldn’t be prouder of the team and the work they are doing.”
Odne has recently launched a Priority Access Program (PAP) for its innovative Root Preservation Therapy (RPT) at the AAE annual meeting in Los Angeles. The PAP will form the core of Odne’s scientific and clinical community, transforming endodontics. One initiative of the PAP is to perform a clinical case registry, collecting further knowledge on the clinical use of Odne’s devices for root canal treatment. Participating Endodontists get the chance to be amongst the first users of Odne’s devices and provide valuable use-related and scientific feedback.
Odne Fill is the first FDA-cleared light-curing, injectable endodontic obturation material. Odne Fill is a hydrogel, a class of biomaterials known for their excellent biocompatibility and hydrophilicity. Due to its water-like viscosity and the ultra-high hydrophilicity in its uncured state, it can flow into complex endodontic structures, such as isthmuses, deltas, and C-shaped canals. Once cured with Odne Cure, the corresponding micro-laser curing device, it provides gap-free root canal sealing and long-term obturation.
OdneClean aims to establish a non-instrumented approach to RPT. A debridement tip as thin as 190µm creates a hydro-dynamic cavitation cloud using physiological saline solution inside the root canal. The cavitation jet removes debris inside the canals and tubules. FDA clearance for OdneClean is expected in H2/2024.
About Steve Fanning
Steve has over 25 years of commercial and general management experience in healthcare, delivering consistent results driving growth with mature businesses and building growth playbooks for newer businesses. In his early career, Steve worked at Johnson & Johnson on the Tylenol, Splenda, and Neutrogena brand businesses. In 2010, he joined Danaher (now Envista) and was promoted to vice president/general manager for the infection prevention and specialties business for Danaher’s Dental Division in 2014. Steve moved to Henry Schein in 2018 as vice president/general manager over the restoratives and endodontics business unit, delivering high-growth results. Recently, Steve worked as CEO at a healthcare startup.
Steve holds a BBA from the University of Michigan with a concentration in marketing and finance, as well as an MBA from the Wharton School at the University of Pennsylvania with a concentration in strategy and marketing.
About Odne
Odne AG (formerly Lumendo AG) has its roots in a groundbreaking collaboration between two renowned Swiss institutions: the Swiss Federal Institutes of Technology in Lausanne and Zürich (EPFL & ETH Zürich). Founded in 2018, Odne’s journey began by licensing cutting-edge technology assets from these esteemed institutes.
Odne is committed to pioneering the future of endodontics through advanced technology and innovative solutions. Endodontics, the field of dental medicine that deals with root canal treatments, has been marred by complexity and unpredictability. Odne is on a mission to change that.
Root canal treatments have long posed challenges for dentists, with traditionally low success rates ranging from 46% to 91%. With over 60 million annual treatments worldwide, these failures result in significant healthcare costs. Odne’s technology platform seeks to address these issues by offering treatment options for both dentists and their patients. Odne’s medical device portfolio, launched in the US in April 2024, tackles problems such as the obturation of complex root canal morphologies.
Recently, Odne Inc, USA, was founded to build the organization to support the US launch.
Odne is backed by venture capital funds focusing on healthcare and dental. These include Revere Partner (NY), an independent venture fund providing capital for cutting-edge innovations in oral and systemic health, and NV Capital (LIE), a family-owned venture capital boutique led by the Series A1 financing. Alongside the lead investors, other renowned funds, such as Dental Innovation Alliance (DIA), Plug&Play, Hatcher, Züricher Kantonalbank, as well as various family offices and angel investors, are supporting Odne’s US market launch.
Odne’s technology platform for Root Preservation Therapy (RPT), including: the first hydro-dynamic cavitation device using saline as the main debridement medium, and the first all-in-one, light-cured filling material.
Disclaimer: Odne Fill and Odne Cure are cleared for use in the USA only. All other Odne devices are currently in development and have not received clearance for clinical use.
For more information, visit www.odne.co.
